Uttam Shrestha1,2, Maria Sciammarella3, Fares Alhassen4, Yerem Yeghiazarians3, Justin Ellin4, Emily Verdin4, Andrew Boyle3,5, Youngho Seo4,6, Elias H Botvinick4,3, Grant T Gullberg4,6. 1. Department of Radiology and Biomedical Imaging, University of California, 185 Berry St., Suite 350, San Francisco, CA, 94143-0946, USA. uttam.shrestha@ucsf.edu. 2. Division of Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, USA. uttam.shrestha@ucsf.edu. 3. Division of Cardiology, Department of Medicine, University of California, San Francisco, CA, USA. 4. Department of Radiology and Biomedical Imaging, University of California, 185 Berry St., Suite 350, San Francisco, CA, 94143-0946, USA. 5. School of Medicine and Public Health, University of Newcastle, Newcastle, Australia. 6. Division of Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
Abstract
BACKGROUND: The objective of this study was to measure myocardial blood flow (MBF) in humans using 99mTc-tetrofosmin and dynamic single-photon emission computed tomography (SPECT). METHODS: Dynamic SPECT using 99mTc-tetrofosmin and dynamic positron emission tomography (PET) was performed on a group of 16 patients. The SPECT data were reconstructed using a 4D-spatiotemporal iterative reconstruction method. The data corresponding to 9 patients were used to determine the flow-extraction curve for 99mTc-tefrofosmin while data from the remaining 7 patients were used for method validation. The nonlinear tracer correction parameters A and B for 99mTc-tefrofosmin were estimated for the 9 patients by fitting the flow-extraction curve [Formula: see text] for K 1 values estimated with 99mTc-tefrofosmin using SPECT and MBF values estimated with 13N-NH3 using PET. These parameters were then used to calculate MBF and coronary flow reserve (CFR) in three coronary territories (LAD, RCA, and LCX) using SPECT for an independent cohort of 7 patients. The results were then compared with that estimated with 13N-NH3 PET. The flow-dependent permeability surface-area product (PS) for 99mTc-tefrofosmin was also estimated. RESULTS: The estimated flow-extraction parameters for 99mTc-tefrofosmin were found to be A = 0.91 ± 0.11, B = 0.34 ± 0.20 (R 2 = 0.49). The range of MBF in LAD, RCA, and LCX was 0.44-3.81 mL/min/g. The MBF between PET and SPECT in the group of independent cohort of 7 patients showed statistically significant correlation, r = 0.71 (P < .001). However, the corresponding CFR correlation was moderate r = 0.39 yet statistically significant (P = .037). The PS for 99mTc-tefrofosmin was (0.019 ± 0.10)*MBF + (0.32 ± 0.16). CONCLUSIONS: Dynamic cardiac SPECT using 99mTc-tetrofosmin and a clinical two-headed SPECT/CT scanner can be a useful tool for estimation of MBF.
BACKGROUND: The objective of this study was to measure myocardial blood flow (MBF) in humans using 99mTc-tetrofosmin and dynamic single-photon emission computed tomography (SPECT). METHODS: Dynamic SPECT using 99mTc-tetrofosmin and dynamic positron emission tomography (PET) was performed on a group of 16 patients. The SPECT data were reconstructed using a 4D-spatiotemporal iterative reconstruction method. The data corresponding to 9patients were used to determine the flow-extraction curve for 99mTc-tefrofosmin while data from the remaining 7 patients were used for method validation. The nonlinear tracer correction parameters A and B for 99mTc-tefrofosmin were estimated for the 9 patients by fitting the flow-extraction curve [Formula: see text] for K 1 values estimated with 99mTc-tefrofosmin using SPECT and MBF values estimated with 13N-NH3 using PET. These parameters were then used to calculate MBF and coronary flow reserve (CFR) in three coronary territories (LAD, RCA, and LCX) using SPECT for an independent cohort of 7 patients. The results were then compared with that estimated with 13N-NH3 PET. The flow-dependent permeability surface-area product (PS) for 99mTc-tefrofosmin was also estimated. RESULTS: The estimated flow-extraction parameters for 99mTc-tefrofosmin were found to be A = 0.91 ± 0.11, B = 0.34 ± 0.20 (R 2 = 0.49). The range of MBF in LAD, RCA, and LCX was 0.44-3.81 mL/min/g. The MBF between PET and SPECT in the group of independent cohort of 7 patients showed statistically significant correlation, r = 0.71 (P < .001). However, the corresponding CFR correlation was moderate r = 0.39 yet statistically significant (P = .037). The PS for 99mTc-tefrofosmin was (0.019 ± 0.10)*MBF + (0.32 ± 0.16). CONCLUSIONS: Dynamic cardiac SPECT using 99mTc-tetrofosmin and a clinical two-headed SPECT/CT scanner can be a useful tool for estimation of MBF.
Authors: G D Hutchins; M Schwaiger; K C Rosenspire; J Krivokapich; H Schelbert; D E Kuhl Journal: J Am Coll Cardiol Date: 1990-04 Impact factor: 24.094
Authors: Ibrahim Danad; Pieter G Raijmakers; Yolande E Appelman; Hendrik J Harms; Stefan de Haan; Mijntje L P van den Oever; Martijn W Heymans; Igor I Tulevski; Cornelis van Kuijk; Otto S Hoekstra; Adriaan A Lammertsma; Mark Lubberink; Albert C van Rossum; Paul Knaapen Journal: J Nucl Med Date: 2012-12-11 Impact factor: 10.057
Authors: J van den Hoff; W Burchert; A R Börner; H Fricke; G Kühnel; G J Meyer; D Otto; E Weckesser; H G Wolpers; W H Knapp Journal: J Nucl Med Date: 2001-08 Impact factor: 10.057
Authors: Simona Ben-Haim; Venkatesh L Murthy; Christopher Breault; Rayjanah Allie; Arkadiusz Sitek; Nathaniel Roth; Jolene Fantony; Stephen C Moore; Mi-Ae Park; Marie Kijewski; Athar Haroon; Piotr Slomka; Kjell Erlandsson; Rafael Baavour; Yoel Zilberstien; Jamshed Bomanji; Marcelo F Di Carli Journal: J Nucl Med Date: 2013-04-11 Impact factor: 10.057
Authors: Maria Sciammarella; Uttam M Shrestha; Youngho Seo; Grant T Gullberg; Elias H Botvinick Journal: J Nucl Cardiol Date: 2017-08-03 Impact factor: 5.952
Authors: Sharmila Dorbala; Karthik Ananthasubramaniam; Ian S Armstrong; Panithaya Chareonthaitawee; E Gordon DePuey; Andrew J Einstein; Robert J Gropler; Thomas A Holly; John J Mahmarian; Mi-Ae Park; Donna M Polk; Raymond Russell; Piotr J Slomka; Randall C Thompson; R Glenn Wells Journal: J Nucl Cardiol Date: 2018-10 Impact factor: 5.952